Latest From I-Mab Biopharma
A review of second quarter biopharma start-up deal-making and financing activity from Strategic Transactions showed a quarter-over-quarter drop in dollars raised despite multiple mega-rounds, including $100m-plus VC deals for SpringWorks and Fusion.
Skyhawk continues its recent spate of deal-making, using its SkyStar platform in a deal with Genentech, which also is looking into neurology with Convelo. AbbVie buys STING specialist Mavupharma, while Recordati pays Novartis $390m for Cushing’s products.
But German Biotech says court summary judgement will have no bearing on MorphoSys's own CD38 antibody MOR202.
In 2018, while biotech venture activity spoke mainly with an American accent, China emerged as the world’s third most active cluster, while the UK led the way in Europe.
- Large Molecule
- Therapeutic Areas
- Immune Disorders
- Company Type
- Parent & Subsidiaries
- I-Mab Biopharma
- Senior Management
Jingwu Zang, MD, PhD, CEO
Jielun Zhu, CFO
Weimin Tang, PhD, EVP, Global Bus. Dev.
Joan Huaqiong Shen, MD, PhD, Pres., R&D
- Contact Info
Phone: 21 6057 8000
Ste. 802, West Tower, 88 Shangke Rd.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.